N-<3-(trifluoromethoxy)phenyl>thiourea | 235101-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<3-(trifluoromethoxy)phenyl>thiourea
• 英文别名: [3-(trifluoromethoxy)phenyl]thiourea；N-[3-(trifluoromethoxy)phenyl]thiourea；1-(3-(Trifluoromethoxy)phenyl)thiourea
• CAS: 235101-42-5
• 化学式: C₈H₇F₃N₂OS
• mdl: MFCD10694257
• 分子量: 236.218
• InChiKey: NUKZFXJCTVTPSO-UHFFFAOYSA-N

物化性质

• 沸点：
  265.4±50.0 °C(Predicted)
• 密度：
  1.495±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-<3-(trifluoromethoxy)phenyl>thiourea 在 sodium dithionite 、 氨 、 sodium ethanolate 、 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 7.5h， 生成 5,6-diamino-2-thioxo-1-[3-(trifluoromethoxy)phenyl]-2,3-dihydropyrimidin-4(1H)-one
  参考文献：
  名称：

  WO2007/120097

  摘要：

  公开号：
• 作为产物：
  描述：

  3-三氟甲氧基苯胺 在 碳酸氢钠 、 Ammonium hydroxide 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 13.0h， 生成 N-<3-(trifluoromethoxy)phenyl>thiourea
  参考文献：
  名称：

  [EN] 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS
  [FR] DÉRIVÉS DE 4-PHÉNYL-N-(PHÉNYL)THIAZOL-2-AMINE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) POUR LE TRAITEMENT, PAR EX., DE TROUBLE LIÉS À L'ANGIOGENÈSE OU INFLAMMATOIRES

  摘要：

  4-苯基-N-(苯基)噻唑-2-胺和4-(吡啶-3-基)-N-(苯基)噻唑-2-胺衍生物以及相应的噻二唑、噻吩、噁唑、噁二唑、咪唑和三唑衍生物和相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。

  公开号：

  WO2021127301A1

文献信息

• Thioxanthine Derivatives and Their Use as Inhibitors of MPO
  申请人：Pivonka Donald

  公开号：US20090286813A1

  公开（公告）日：2009-11-19

  There are disclosed novel compounds of Formula (I) wherein R 1 , X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.

  本发明公开了式（I）的新化合物，其中R1，X和Y如规范中所定义，并且其药学上可接受的盐；以及它们的制备方法，含有它们的组合物以及它们在治疗中的用途。这些化合物是MPO酶的抑制剂，因此在治疗或预防神经炎性疾病，心血管和脑血管动脉粥样硬化性疾病和周围动脉疾病以及呼吸系统疾病中特别有用。
• Riluzole Series. Synthesis and in Vivo “Antiglutamate” Activity of 6-Substituted-2-benzothiazolamines and 3-Substituted-2-imino-benzothiazolines
  作者：Patrick Jimonet、François Audiau、Michel Barreau、Jean-Charles Blanchard、Alain Boireau、Yvette Bour、Marie-Annick Coléno、Adam Doble、Gilles Doerflinger、Claudine Do Huu、Marie-Hélène Donat、Jean Marie Duchesne、Pierre Ganil、Claude Guérémy、Eliane Honoré,、Bernard Just、Roselyne Kerphirique、Sylvie Gontier、Philippe Hubert、Pierre M. Laduron、Joseph Le Blevec、Mireille Meunier、Jean-Marie Miquet、Conception Nemecek、Martine Pasquet、Odile Piot、Jeremy Pratt、Jean Rataud、Michel Reibaud、Jean-Marie Stutzmann、Serge Mignani

  DOI：10.1021/jm980202u

  日期：1999.7.1

  Two series of analogues of riluzole, a blocker of excitatory amino acid mediated neurotransmission, have been synthesized: monosubstituted 2-benzothiazolamines and 3-substituted derivatives. Of all the compounds prepared in the first series, only 2-benzothiazolamines bearing alkyl, polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent anticonvulsant activity against administration of glutamic acid in rats. The most active compounds displaying in vivo "antiglutamate" activity were the 6-OCF3 (riluzole), 6-OCF2CF3, 6-CF3, and 6-CF2CF3 substituted derivatives with ED50 values between 2.5 and 3.2 mg/kg i.p. Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a beta-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones. The most potent derivatives were 2-imino-3-(2-methylthio)- and 2-imino-3-(2-methylsulfinyl)-ethyl-6-trifluoromethoxybenzothiazlines (61 and 64, ED50 = 10 and 1.1 mg/kg i.p., respectively). In addition, intraperitoneal administration of some of the best benzothiazolines protected mice from mortality produced by hypobaric hypoxia.
• THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO
  申请人：AstraZeneca AB

  公开号：EP2010534A1

  公开（公告）日：2009-01-07
• ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF
  申请人：Ikena Oncology, Inc.

  公开号：US20210230153A1

  公开（公告）日：2021-07-29

  The present invention provides AHR agonists, compositions thereof, and methods of using the same.
• [EN] THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO<br/>[FR] DÉRIVÉS DE THIOXANTHINE ET LEUR EMPLOI EN TANT QU'INHIBITEURS DE MPO
  申请人：ASTRAZENECA AB

  公开号：WO2007120097A1

  公开（公告）日：2007-10-25

  [EN] There are disclosed novel compounds of Formula (I) wherein R¹, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
  [FR] La présente invention porte sur de nouveaux composés de Formule (I) où R¹, X et Y sont tels que définis dans la description de l'invention, et des sels de qualité pharmaceutique desdits composés ; ainsi que sur leurs procédés de synthèse, des compositions les incluant et leurs applications en thérapie. Les composés sont des inhibiteurs de l'enzyme MPO et peuvent donc être en particulier employés dans le traitement prophylactique ou thérapeutique de troubles neuroinflammatoires, de troubles athérosclérotiques cardio- et cérébrovasculaires et de maladies artérielles périphériques et de troubles respiratoires.